一、情况概述 （一）现金管理目的 证券代码：600055 证券简称：万东医疗 编号：临 2023-023 北京万东医疗科技股份有限公司关于 使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：1.3 亿元 履行的审议程序：2023 年4 月17 日召开的第九届董事会第九次会议、 第九届监事会第九次会议及 2023 年 5 月 12 日召开的 2022 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金进行现金管理的议案》。 北京万东医疗科技股份有限公司（以下简称"公司"）为提高募集资 金效率，合理利用部分闲置募集资金，在确保不影响募集资金项目建设和 使用、募集资金安全的情况下，增加公司的收益，为公司及股东获取更多 回报。 （二）现金管理金额 本次现金管理总金额为 1.3 亿元。 （三）资金来源及相关情况 本次现金管理的资金来源为闲置募集资金。 经中国证券监督管理委员会《关于核准北京万东医疗科技股份有限公 司非公开发行股票的批复》 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥594,330,937.42, representing a 30.19% increase compared to ¥456,521,773.90 in the same period last year[4]. - The net profit attributable to shareholders for the same period was ¥76,040,693.09, up 28.21% from ¥59,311,322.24 year-on-year[4]. - The basic earnings per share for the first half of 2023 was ¥0.108, a 12.50% increase from ¥0.096 in the same period last year[4]. - The total comprehensive income for the period was CNY 77,642,229.10, compared to CNY 59,559,461.94 in the previous year, marking a 30.3% increase[169]. - The total profit for the period was CNY 93,986,034.32, compared to CNY 70,980,527.32 in the previous year, indicating a growth of 32.4%[169]. Cash Flow and Assets - The net cash flow from operating activities was ¥23,207,023.89, reflecting an 11.15% increase from ¥20,878,247.01 in the previous year[4]. - The company's cash and cash equivalents decreased by 16.07% to CNY 2,720,600,620.54, compared to CNY 3,241,421,962.85 at the end of the previous year[35]. - The cash inflow from operating activities for the first half of 2023 was approximately ¥781.12 million, an increase of 33.2% compared to ¥586.01 million in the same period of 2022[165]. - The total assets at the end of the reporting period were ¥5,262,961,528.92, showing a slight increase of 0.01% compared to ¥5,262,599,175.73 at the end of the previous year[4]. - The total liabilities decreased to CNY 2,769,663,206.47, indicating improved financial health[195]. Research and Development - Research and development expenses increased by 30.86% to CNY 64,569,201.91, reflecting the company's commitment to enhancing R&D investment[33]. - The company is actively developing AI projects related to imaging equipment to meet clinical needs and enhance technological capabilities[29]. - Research and development expenses rose to approximately $56.56 million, up from $35.59 million, indicating a significant increase of 58.9%[156]. Market and Product Development - The company specializes in the research, production, and sales of large medical imaging equipment, including DR, MRI, CT, DSA, and DM systems[20]. - Sales of CT products saw a significant increase of nearly 200% year-on-year, becoming the main driver of revenue growth during the reporting period[28]. - The company launched new products including the 32-slice CT and 50kW mobile DR, enhancing its product lines in CT and DR[24]. - The company plans to expand its market presence and invest in new product development to drive future growth[200]. Related Party Transactions - The company reported a total of 58,511,278.84 in related party transactions, accounting for 11.34% of similar transaction amounts[69]. - The company has committed to maintaining independence in assets, personnel, finance, business, and institutions with respect to Wandong Medical[66]. - The company will minimize related party transactions and ensure fairness in pricing according to market principles[68]. Financial Health and Stability - The company confirmed that there were no major risks that could significantly impact its operations during the reporting period[92]. - The financial statements were prepared in accordance with the relevant accounting standards and accurately reflect the company's financial status[99]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[92]. Future Outlook - Future guidance indicates a cautious but optimistic outlook for revenue growth in the upcoming quarters[200]. - The company is focusing on enhancing its technology capabilities to improve operational efficiency and customer satisfaction[200].

Financial Performance - The company's operating revenue for Q1 2023 was ¥255,084,691.08, representing a year-on-year increase of 21.12%[6] - The net profit attributable to shareholders for Q1 2023 was ¥30,438,016.42, reflecting a year-on-year growth of 23.57%[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,282,857.58, up 24.34% year-on-year[6] - Total revenue for Q1 2023 reached ¥255,084,691.08, a 21.1% increase from ¥210,601,112.63 in Q1 2022[24] - Operating profit for Q1 2023 was ¥35,458,280.90, compared to ¥30,482,372.71 in Q1 2022, reflecting an increase of 16.4%[27] - Net profit for Q1 2023 amounted to ¥29,673,219.40, up from ¥25,382,468.15 in Q1 2022, representing a growth of 16.5%[29] - The company reported a total comprehensive income of ¥29,673,219.40 for Q1 2023, compared to ¥25,382,468.15 in Q1 2022, reflecting an increase of 16.5%[29] Cash Flow - The net cash flow from operating activities was -¥44,623,764.36, a decrease of 74.35% compared to the same period last year[6] - Cash flow from operating activities showed a net outflow of ¥44,623,764.36 in Q1 2023, worsening from a net outflow of ¥25,595,019.71 in Q1 2022[31] - Net cash flow from investing activities was -$153,040,931.44, compared to $128,582,285.46 in the previous period[32] - Total cash inflow from financing activities reached $2,090,259,364.94, while cash outflow was $636,779.93, resulting in a net cash flow of $2,053,539,364.94[32] - The ending cash and cash equivalents balance was $3,033,170,415.68, down from $3,231,471,891.41 at the beginning of the period[32] - Cash inflow from investment activities totaled $50,831,601.16, significantly lower than $162,717,036.16 in the previous period[32] - Cash outflow for capital expenditures was $3,872,532.60, compared to $1,134,750.70 in the previous period[32] - The company received $50,000,000.00 from investment recoveries, down from $155,500,000.00 previously[32] - The company reported a significant increase in cash inflow from financing activities, primarily due to new investments received[32] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥5,270,779,752.96, showing a slight increase of 0.16% from the end of the previous year[9] - The equity attributable to shareholders at the end of Q1 2023 was ¥4,635,842,013.21, which is a 0.66% increase from the previous year-end[9] - The total current assets were CNY 4,273,359,853.97, showing a marginal increase from CNY 4,266,343,912.23[20] - The total current liabilities decreased to CNY 470,583,949.12 from CNY 492,076,591.29, a reduction of about 4.4%[22] - The non-current assets totaled CNY 997,419,898.99, slightly up from CNY 996,255,263.50[22] - The total liabilities were CNY 486,248,381.68, down from CNY 507,740,023.85, indicating a decrease of approximately 4.2%[22] - Total liabilities as of Q1 2023 were ¥530,488,831.82, a decrease from ¥551,981,473.99 in the previous year[24] - Total equity attributable to shareholders reached ¥4,635,842,013.21 in Q1 2023, up from ¥4,605,403,996.79 in Q1 2022[24] Earnings and Expenses - The company's basic earnings per share for Q1 2023 was ¥0.043, down 6.52% year-on-year[6] - The weighted average return on equity for Q1 2023 was 0.66%, a decrease of 0.36% compared to the same period last year[6] - Research and development expenses increased to ¥28,849,435.87 in Q1 2023, compared to ¥24,860,818.21 in Q1 2022, marking a rise of 15.9%[27] - Sales expenses rose to ¥47,730,558.94 in Q1 2023, up from ¥39,339,624.00 in Q1 2022, indicating a 21.5% increase[27] Financial Assets - The increase in trading financial assets by 149.50% was due to the use of temporarily idle funds to purchase financial products[12] - The company reported a decrease in cash flow from investing activities by 219.02% due to the purchase of financial products with temporarily idle funds[12] - The company reported a significant increase in financial assets, with trading financial assets rising to CNY 250,422,580.82 from CNY 100,369,008.22, a growth of about 149.5%[20] Related Party Transactions - The company has not disclosed any related party relationships among the top shareholders, indicating no known concerted actions as per the regulations[18]

一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、 准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的 法律责任。 二、 公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人谢宇峰、主管会计工作负责人井晓权及会计机构负责人（会计主管人员） 杨征声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2022年度利润分配预案为以公司最新总股本703,061,058股为基数，每10股派发现金 股利1.20元（含税），合计派发现金红利84,367,326.96元。上述利润分配方案尚需提交 股东大会审议通过。 六、 前瞻性陈述的风险声明 √适用 □不适用 否 九、 是否存在半数以上董事无法保证公司所披露年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本年度报告中描述可能存在的相关风险，敬请投资者予以关注，详见本年 度报告有关章节中关于公司未来发展可能面对的风险等内容。 2022 年年度报告 公司代码：600055 公司简 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：600055 证券简称：万东医疗 北京万东医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 本报告期比 年初至报告 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|---------------------------|----------------|----------------------------------| | ...

2022 年半年度报告 公司代码：600055 公司简称：万东医疗 北京万东医疗科技股份有限公司 2022 年半年度报告 1 / 125 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、 准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人谢宇峰、主管会计工作负责人井晓权及会计机构负责人（会计主管人员） 杨征声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2022年中期不进行利润分配或资本公积转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告中所涉及未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质 承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风 ...

2021 年年度报告 公司代码：600055 公司简称：万东医疗 北京万东医疗科技股份有限公司 2021 年年度报告 1 / 163 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、 准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的 法律责任。 二、 公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人谢宇峰、主管会计工作负责人井晓权及会计机构负责人（会计主管人员） 杨征声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2021年度利润分配预案为以公司最新总股本703,061,058股为基数，每10股派发现金 股利1.00元（含税），合计派发现金红利70,306,105.80元。上述利润分配方案尚需提交 股东大会审议通过。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告中所涉及未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质 承诺，请投资者注意投资风险。 七、 是否存在被控 ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：600055 证券简称：万东医疗 北京万东医疗科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | --- | |----------------------------------------------|------------------|------------------|---------------------------------------| | 项目 | | 本报告期 | 本报告期比上年同 期增减变动幅度 (% ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：600055 证券简称：万东医疗 北京万东医疗科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|------------------------------------------|----------------|----------------------------- ...

2021 年半年度报告 公司代码：600055 公司简称：万东医疗 北京万东医疗科技股份有限公司 2021 年半年度报告 1 / 121 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人谢宇峰、主管会计工作负责人井晓权及会计机构负责人（会计主管人员） 杨征声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2021年中期不进行利润分配或资本公积转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告中所涉及未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承 诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 ...